IPC is pleased to introduce and welcome our five newest Councilors for 2022: Pravit Asawanonda, Sunil Dogra, Benjamin Ehst, Filip Rob, and Tsen-Fang Tsai. These individuals were confirmed by the IPC Board of Directors during the European Academy of Dermatology and Venereology (EADV) Congress in September.
Psoriasis and tuberculosis have long gone hand-in-hand. This is especially true in certain parts of the world, where latent tuberculosis continues to be widespread. With one-quarter of the global population estimated to have latent tuberculosis, guidelines to properly screen for and treat tuberculosis in psoriasis patients are critical.
The IPC is a proud supporter of World Psoriasis Day by uniting for action with IFPA to advance care and change the perception of psoriatic disease. Watch the video below to hear IPC’s key opinion leaders from around the world discuss this year’s theme – psoriasis and its impact on mental health.
Prof. Christine Bundy shares how clinicians can center mental health in psoriasis care — and what to look out for in your patients.
The Global Psoriasis Atlas (GPA) is a joint project of the ILDS (International League of Dermatological Societies), IFPA (International Federation of Psoriasis Associations), and IPC (International Psoriasis Council) delivered by staff based at the University of Manchester. Its goal is to provide the benchmark on the burden of psoriasis in all countries and regions throughout the world using comprehensive epidemiological data to inform research, policy, and healthcare.
Personalized care has become increasingly utilized in the past two few decades, evolving as we have gained a greater understanding of the human genome and recognized the importance of shifting away from a “one size fits all” approach to medicine.
New resource page that includes the latest articles, downloads, and related press releases on GPP to assist with diagnosing and treating this rare disease.
Patients with psoriasis are at increased risk for cardiovascular disease —and lack of physical activity may be a driving cause.
The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.
Researchers at Cardiff University have created and launched The Official DLQI App, designed to measure the quality of life for people with skin conditions. The app is free to download in the Apple and Android stores and is now available in seven languages!
Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best evidence review. In 2021, IPC supported the BIOMAP collaboration to complete a systematic review on biomarkers. Last month, two new lay summaries were published by BIOMAP on this project.
Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years.
